With the development of structural cryo-microscopy in recent years, pharmaceutical companies are very interested in these approaches in order to better characterise the structural organisation of their complex interests. Electron cryo-microscopy has undergone a real revolution in recent years. This makes it possible to obtain the structure of biological complexes at a molecular level from images taken under the electron microscope. The CryoVir project will help to understand at the molecular level how molecules of interest interact with their protein targets. This work will also make it possible to see the impact of these molecules on viral particles. The results of this work will allow in the longer term the rational and targeted development of new molecules allowing a better controlled interaction with their protein targets and thus with a better controlled antiviral and anti-inflammatory action. This will make it possible to design inhibitory molecules with a stronger affinity and specificity. The project involves: three academic partners: INSERM (project carrier), CNRS and the University of Montpellier, cotutelles of the CBS laboratory (Centre de Biochemie Structurale). Only INSERM and CNRS will report expenditures on the project and a private partner: ABIVAX company. The project will take place within the PCME Plateau de Cryo-microscopy Electronique.